中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma

文献类型：期刊论文

作者Wang, Fangzheng1,2,3,4; Jiang Chuner1,5; Wang Lei1,2,3,4; Yan Fengqin1,2,3,4; Ye Zhimin1,2,3,4; Sun Quanquan1,2,3,4; Liu Tongxin1,2,3,4; Fu Zhenfu1,2,3,4; Jiang Yangming6
刊名MEDICINE
出版日期2020-09-25
卷号99
关键词concurrent chemotherapy induction chemotherapy intensity-modulated radiotherapy nasopharyngeal carcinoma prognosis toxicity
ISSN号0025-7974
DOI10.1097/MD.0000000000022283
通讯作者Wang, Fangzheng(wangfz76@126.com) ; Jiang Yangming()
英文摘要For patients with locoregionally advanced nasopharyngeal carcinoma (NPC), induction chemotherapy (IC) regimens based on TPF (docetaxel, cisplatin, and 5-fluorouracil), TP (docetaxel and cisplatin), and GP (gemcitabine and cisplatin) have shown excellent survival outcomes as the first-line therapy; however, no trials comparing the efficacy and safety of TPF, TP, and GP have been reported. We report 2 phase II trials comparing the treatment outcomes and side effects of 3 different IC regimens followed by concurrent chemoradiotherapy in locoregionally advanced patients with NPC. A total of 206 locoregionally advanced patients with NPC treated with a combination treatment from January 2012 to January 2014 were enrolled in the 2 studies. The patients received TPF-, TP-, and GP-based IC regimens every 3 weeks, followed by intensity-modulated radiotherapy and concurrent therapy with cisplatin every 3 weeks. After a median follow-up duration of 47 months (10-60 months), the 3-year local recurrence-free survival, regional recurrence-free survival, distant metastases-free survival, progression-free survival, and overall survival rates were 96.4%, 100%, 87.7%, 86%, and 94.7% in the TPF arm; 91.7%, 95.9%, 91.9%, 85.2%, and 92% in the TP arm; 98.6%, 100%, 89.0%, 87.6%, and 89.2% in the GP arm. The survival differences among the 3 arms were not statistically significant (P> .05). The multivariate analysis demonstrated that the IC regimen was not an independent prognostic factor for any survival outcomes. The patients in the TP arm experienced significantly lower grade 3/4 toxicities than the patients in the other 2 arms. TP-based IC regimen has similar efficacy compared with TPF- and GP-based IC regimens; however, TP-based IC regimen has a lower toxicity profile.
WOS关键词COMPARING NEOADJUVANT CHEMOTHERAPY ; PHASE-II TRIAL ; RANDOMIZED-TRIAL ; STAGING SYSTEM ; 7TH EDITION ; CISPLATIN ; DOCETAXEL ; CHEMORADIOTHERAPY ; GEMCITABINE ; FLUOROURACIL
资助项目Medical and Health Science and Technology Program of Zhejiang Province[2020KY084] ; Medical and Health Science and Technology Program of Zhejiang Province[2019KY041] ; Medical and Health Science and Technology Program of Zhejiang Province[2013KYB033] ; Medical and Health Science and Technology Program of Zhejiang Province[2009B026] ; Medical and Health Science and Technology Program of Zhejiang Province[2006A016] ; Medical and Health Science and Technology Program of Zhejiang Province[2005B012] ; Medical and Health Science and Technology Program of Zhejiang Province[2004B014] ; National Natural Science Foundation of China[81502646] ; National Natural Science Foundation of China[81502647]
WOS研究方向General & Internal Medicine
语种英语
WOS记录号WOS:000579445400031
出版者LIPPINCOTT WILLIAMS & WILKINS
资助机构Medical and Health Science and Technology Program of Zhejiang Province ; National Natural Science Foundation of China
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/104524]  
专题中国科学院合肥物质科学研究院
通讯作者Wang, Fangzheng; Jiang Yangming
作者单位1.Univ Chinese Acad Sci, Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China
2.Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China
3.Chinese Acad Sci, Inst Canc Res & Basic Med Sci, Hangzhou, Zhejiang, Peoples R China
4.Zhejiang Canc Hosp, Zhejiang Key Lab Radiat Oncol, Hangzhou, Zhejiang, Peoples R China
5.Zhejiang Canc Hosp, Dept Breast Tumor Surg, Hangzhou, Zhejiang, Peoples R China
6.Chinese Acad Sci, Inst Remote Sensing & Digital Earth, Dept Digital Earth, Beijing, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Fangzheng,Jiang Chuner,Wang Lei,et al. Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma[J]. MEDICINE,2020,99.
APA Wang, Fangzheng.,Jiang Chuner.,Wang Lei.,Yan Fengqin.,Ye Zhimin.,...&Jiang Yangming.(2020).Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma.MEDICINE,99.
MLA Wang, Fangzheng,et al."Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma".MEDICINE 99(2020).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。